ArticleJournal of translational medicine2026
Decomposing the genetic risk of autism spectrum disorder into discrete molecular subtypes underlie clinical heterogeneity based on transcriptome profile.
Article in Journal of translational medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAutism spectrum disorder (ASD) is a highly heterogeneous neurodevelopmental condition with a complex genetic architecture. While over a thousand risk genes have been cataloged, a fundamental challenge remains how this vast genetic landscape translates into diverse clinical manifestations. To address this, we propose a "many-to-few" framework, shifting from traditional "many-to-one" convergence model toward an intrinsic organizational architecture where disparate ASD risk genes funnel into discrete molecular dimensions.
methodsBy leveraging similarity network fusion (SNF) to integrate bulk and single-nucleus RNA sequencing data, we decomposed the 311 ASD reliable risk genes into three stable, spatiotemporally distinct molecular subtypes. These subtypes represent coordinated expression programs that integrate functionally diverse genes, such as those involved in synaptic signaling, mRNA stabilization, and histone modification. Mapping de novo variants from the SPARK cohort onto these subtypes enabled stratification of probands into three genetically defined subgroups (S1-S3) with divergent clinical profiles.
resultsTranscriptomic decomposition partitioned the 311 reliable risk genes into three stable molecular subtypes, Synaptic Signaling (C1), mRNA Stabilization (C2), and Histone Modification (C3), exhibiting divergent spatiotemporal trajectories and cell-type-specific enrichment. Patient subgroups stratified based on these molecular subtypes displayed significant differences in adaptive functioning, core symptoms, and psychiatric comorbidities, while a reference group (S4) lacking de novo variants of these highly reliable ASD risk genes exhibited the most preserved functions. Furthermore, diverging rare and common genetic liability profiles across subgroups, particularly between S1 and S3, provide empirical support for a molecular subtype-based liability threshold model.
conclusionsOur study establishes a biologically informed framework that links intrinsic molecular subtypes to multidimensional phenotypic constellation, advancing mechanistic insight and offering translational potential for precision stratification and intervention.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.